A review of cancer immunotherapy: from the past, to the present, to the future
K Esfahani, L Roudaia, N Buhlaiga, SV Del Rincon… - Current …, 2020 - mdpi.com
A review of cancer immunotherapy: from the past, to the present, to the future Page 1 S87
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …
Current Oncology, Vol. 27, Supp. 2, April 2020 © 2020 Multimed Inc. REVIEW ARTICLE A …
Description and proposed management of the acute COVID-19 cardiovascular syndrome
Coronavirus disease 2019 (COVID-19) is a rapidly expanding global pandemic caused by
severe acute respiratory syndrome coronavirus 2, resulting in significant morbidity and …
severe acute respiratory syndrome coronavirus 2, resulting in significant morbidity and …
Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer
C Dolladille, S Ederhy, M Sassier, J Cautela… - JAMA …, 2020 - jamanetwork.com
Importance Limited information is available on the safety of a rechallenge with an immune
checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). Objective To identify …
checkpoint inhibitor (ICI) after an immune-related adverse event (irAE). Objective To identify …
Multisystem immune-related adverse events associated with immune checkpoint inhibitors for treatment of non–small cell lung cancer
Importance The spectrum of individual immune-related adverse events (irAEs) from anti–
programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune …
programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) immune …
Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors
AM Stamatouli, Z Quandt, AL Perdigoto, PL Clark… - Diabetes, 2018 - Am Diabetes Assoc
Insulin-dependent diabetes may occur in patients with cancers who are treated with
checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two …
checkpoint inhibitors (CPIs). We reviewed cases occurring over a 6-year period at two …
Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology
JA Thompson, BJ Schneider, J Brahmer… - Journal of the National …, 2019 - jnccn.org
The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to
provide guidance on the management of immune-related adverse events resulting from …
provide guidance on the management of immune-related adverse events resulting from …
Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer
A Simonaggio, JM Michot, AL Voisin, J Le Pavec… - JAMA …, 2019 - jamanetwork.com
Importance Although immune checkpoint inhibitors (ICIs), such as anti–PD-1 (programmed
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …
cell death 1) or anti–PD-L1 (programmed cell death 1 ligand 1), have proved effective in …
Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint Inhibitor–Associated myocarditis
L Zhang, DA Zlotoff, M Awadalla, SS Mahmood… - Circulation, 2020 - Am Heart Assoc
MACE independent of age, sex, lowest left ventricular ejection fraction, and time of initiation
(hazard ratio, 0.27 [95% CI, 0.09–0.84]; P= 0.024). Patients receiving corticosteroids within …
(hazard ratio, 0.27 [95% CI, 0.09–0.84]; P= 0.024). Patients receiving corticosteroids within …
Immune-related thyroiditis with immune checkpoint inhibitors
PC Iyer, ME Cabanillas, SG Waguespack, MI Hu… - Thyroid, 2018 - liebertpub.com
Background: Although immune-related thyroiditis (irT) with immune checkpoint inhibitors
(ICI) is a common consequence, its natural course and management recommendations are …
(ICI) is a common consequence, its natural course and management recommendations are …
Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer—a phase 1 study
TS Uldrick, PH Gonçalves, M Abdul-Hay… - JAMA …, 2019 - jamanetwork.com
Importance Anti− PD-1 (anti− programmed cell death 1) and anti− PD-L1 (anti− programmed
cell death ligand 1) regimens are preferred therapies for many cancers, including cancers …
cell death ligand 1) regimens are preferred therapies for many cancers, including cancers …